WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

Press/Media

PeriodDec 12 2019

Media coverage

1

Media coverage

  • TitleWindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    Country/TerritoryJordan
    Date12/12/19
    PersonsMartin Edelman